Clearant, Inc. Reports 1st Quarter 2009 Revenue Results

LOS ANGELES, CA, May 19 (MARKET WIRE) --
Clearant, Inc. (OTCBB: CLRA), owner of the Clearant Process(R) which is
designed to substantially reduce all types of pathogens in biological
products, including HIV, today announced that revenues for the 1st
quarter ended March 31, 2009 increased 2% to $0.47 million compared to
$0.46 million for the 1st quarter ended March 31, 2008.

Direct distribution revenue increased 42% to $0.44 million for the 1st
quarter ended March 31, 2009, compared to $0.31 million for 1st quarter
ended March 31, 2008. Revenues from licensing, fee for service, and
contract research activities which the Company has been de-emphasizing,
decreased to $37,000 for the 1st quarter ended March 31, 2009 from
$158,000 for the 1st quarter ended March 31, 2008.

More detailed information about Clearant's 1st quarter 2009 results can be
found in its Quarterly Report filed with the Securities and Exchange
Commission on May 15, 2009.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process(R),
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the underlying
tissue implant or protein. The Company has distributed implants
sterilized by the Clearant Process(R) directly to surgeons, hospitals and
clinics since June 2006. In addition, Clearant licenses the Clearant
Process(R), and provides its patented sterilization services, to tissue
banks and other biological products manufacturers. To date more than
8,000 patients have been successfully implanted with Clearant Process(R)
sterile implants supplied by one of the Company's licensed partners. The
Clearant Process(R), unlike its various competitors, is applied in the
final packaging and reduces all types of pathogens for products across
many market segments including tissue implants, plasma proteins,
recombinant products, medical devices and blood products. For more
information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this
press release are forward looking and made pursuant to the Safe Harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect numerous assumptions and involve a
variety of risks and uncertainties, many of which are beyond the company's
control that may cause actual results to differ materially from stated
expectations. These risk factors include, among others, limited financial
resources and difficulty in developing and exploiting proprietary
technologies and additional risk factors as discussed in the reports filed
by the Company with the Securities and Exchange Commission, which are
available on its website at http://www.sec.gov.

Contact:
Clearant, Inc.
Jon Garfield
Chief Executive Officer
310-479-4570
www.clearant.com

Copyright 2009, Market Wire, All rights reserved.

-0-